EIF3a upregulation in lung cancer patients also correlated with their response to platinum-based chemotherapy and contributed to increased cisplatin (cis-dichlorodiammine platinum(II) (CDDP)) sensitivity [52]. Here, EIF3A is linked to lung cancer.